Background: While tumor-tissue remains the 'gold standard' for genetic analysis in cancer patients, it is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis from blood samples. Here, we broaden our previous study on the clinical validation of plasma DNA in metastatic colorectal cancer patients, by evaluating its clinical utility under standard management care.
Introduction
Mutation screening of RAS to predict response to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer (mCRC) patients [1] [2] [3] [4] [5] [6] [7] is mandatory to maximize patient benefit. Currently, it is carried out from tumor-tissue. However, this 'gold-standard' is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis from blood samples appearing as a 'liquid biopsy' approach [8] [9] [10] [11] . ctDNA analysis constitutes a hopeful approach to provide a minimally invasive tumor molecular test for cancer patients [12] [13] [14] [15] [16] . In particular, ctDNA analysis is evaluated as a theragnostic test when the mutational status of specific gene is predictive of the therapeutic response. Sequencingand targeted-based approaches are taken into consideration. While sequencing approaches such as NGS enable high gene coverage [17] , targeted approach such as Q-PCR-based techniques (Beaming, dPCR or refined Q-PCR) beneficiates from higher sensitivity to detect previously known hotspot mutations. Based upon breakthrough information on ctDNA fragmentation and size [18, 19] , we developed a Q-PCR-based-method (IntPlex V R ) which is the first multiplexed test for ctDNA. We demonstrated the first clinical validation of ctDNA analysis in oncology [16] by detecting KRAS exon 2 and BRAF V600E point mutations in mCRC patients, and showed that a blood test could replace tumor-section analysis.
Here, we broaden our previous validation of ctDNA [16] by comparing ctDNA analysis and tumor-tissue analysis in a prospective, multicenter and blinded study with significant differences with our previous study: (i) ctDNA analysis was just-intime carried out allowing direct comparison of the data turnaround-time in the course of standard routine practice; (ii) the mutation status from plasma analysis was determined with a >50-fold higher sensitivity than in this earlier study; (iii) extended RAS hotspot mutations was tested. This study demonstrates clinical utility of ctDNA analysis and paves the way in considering it as next generation of companion diagnostics.
Materials and methods

Study design and participants
Kplex2 is a blinded multicenter prospective study (n ¼ 11 clinical centers). A total 140 mCRC patients with requested KRAS mutational status for anti-EGFR therapeutic decision-making were enrolled. Patients were naive for anti-EGFR treatment. Full inclusion criteria and regulatory aspects are described in supplementary data, p. 2, available at Annals of Oncology online.
Masking
Clinical data and results of standard and index tests were collected prospectively by our Biostatistic Unit. Readers of the two tests were blinded to the results of the other test.
Mutation testing from tumor-tissue and plasma
Tumor-tissue analysis was carried out in each clinical center participating to the study in the context of the standard management care of mCRC patients considered for anti-EGFR treatment. According to our specific pre-analytical guideline for ctDNA analysis [20] (see supplementary data, pp. 2-9, available at Annals of Oncology online for more details). CtDNA analysis was just-in-time centrally carried out on one of the sites. ctDNA analysis was carried out from using 2 ml plasma for testing 28 different mutations testing. Mutation testing from plasma was carried out by using the IntPlex method applied as previously described [16] without any mutation sensitivity threshold so enabling a >50-fold higher sensitivity while keeping high analytical specificity and sensitivity due to the use of two negative and one positive control in each run and quality controls with regards to plasma pre-analytical conditions.
Outcomes
The outcomes consisted in (i) comparing the data turnaround time of tumor-tissue and plasma analysis, and (ii) studying concordance of the data obtained from both diagnostic approaches; the tumor-tissue analysis was regarded as the gold standard. The outcomes were carried out in blinded conditions where KRAS exon 2 and BRAF V600E mutation tests were made by both methods in 121 and 97 patients, respectively. The RAS extended mutation test as determined by ctDNA analysis was carried out in blinded conditions only for the patients scored WT for KRAS exon 2 and BRAF (n ¼ 50) (see supplementary data, pp. 7-8, available at Annals of Oncology online).
Post hoc analysis
The study has two post hoc analyses. The first post hoc analysis consisted in examining the discordance and the factors potentially impacting it. The second post hoc analysis consisted of obtaining a direct mutation profiling when considering the actionable RAS and BRAF mutations carried out by both analytical approaches in a maximum of patients (see supplementary data, p. 9 for more detailed methodology, available at Annals of Oncology online).
Statistical analysis
The study has been designed with a false positive rate ¼ 10%, a true positive rate ¼ 85% and a ratio (percentage of patients with a negative test ¼ nonmutated/percentage of patients with a positive test ¼ mutated) ¼ 60/ 40 ¼ 1.5. Finally, 115 patients assessable (with determination of status by both methods) were required [22] . The diagnostic utility of the blood test was assessed using sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Sensitivity reflects the diagnostic performance in detecting mutated patients, and specificity reflects the performance in detecting non-mutated patients. The PPV and NPV are the proportions of mutated (positive results) and WT predicted patients (negative results) that are really mutant (true positive result) and WT, respectively.
Results
Flow of participants
Results are presented according to STARD criteria (Figure 1 ; supplementary data, pp. 10-14, available at Annals of Oncology online). A total of 140 mCRC patients were enrolled from the 11 clinical centers (supplementary data, pp. 15-16, available at Annals of Oncology online). All plasma samples compliant for technical inclusion criteria were correctly analyzed (100% success rate). Finally, 121 mCRC participants were selected (Figure 1 ; supplementary data, p. 10, available at Annals of Oncology online). Baseline demographic, clinical characteristics and tumortissue analysis characteristics are presented in Table 1 (n ¼ 121) (detailed supplementary data, pp. 13-18, available at Annals of Oncology online). 
Comparison of data turnaround time
The median delay between (i) inclusion and results communication was 18 days (n ¼ 121; 4-288 days) for tumor-tissue analysis while 7 days (n ¼ 121; 1-72 days) for plasma analysis; (ii) tissue sample reception by the hospital laboratory and communication of the results was 12 days (n ¼ 83; 3-273 days) but only 2 days between the plasma sample reception by our laboratory and results communication (n ¼ 121; 0-10 days) ( Table 2) .
Concordance study between ctDNA and tumortissue analysis Evaluation of concordance was detected considering tumor-tissue analysis as the 'gold standard'. KRAS exon 2 point mutations (n ¼ 121). Fifty-three mutant tumor-tissue samples (44%) and 71 mutant plasma samples (59%) were determined. Forty-five mutant samples (37%) and 42 WT samples (35%) were concordant. Eight WT plasma samples were found mutant by tumor-tissue analysis (7%). Conversely, 26 WT tumor-tissue samples were found mutant by plasma analysis (21.5%). Sensitivity, specificity, PPV and NPV were 85%, 62%, 63% and 84%, respectively (Table 2B; detailed  data in supplementary Table S8 , available at Annals of Oncology online).
BRAF V600E point mutation. Detection of the BRAF V600E point mutation was tested for 97 patients under routine standard management care and in 127 plasma samples. Concordance analysis was finally evaluated in 97 patients. Seven mutant tumor-tissue samples (7%) and 14 mutant plasma samples (14%) were determined. Four mutant samples and 80 WT samples were concordant. Three WT plasma samples were found mutant by tumor-tissue analysis. Inversely, 10 WT tumor-tissue samples were found mutant by plasma analysis. Sensitivity, specificity, PPV and NPV were 57%, 89%, 29% and 96%, respectively (Table 2B; detailed data in supplementary Table S8 , available at Annals of Oncology online). Table 2 . Blinded comparison study between tumor-tissue and plasma ctDNA analysis: (A) data turnaround time (n 5 121); (B) concordance study for the detection of KRAS exon two-point mutations (n 5 121), BRAF V600E (n 5 97), KRAS exon 3 and 4 (n 5 34) and NRAS exon 2 and 3 (n 5 34)
Comparison of data turnaround time between tumor-tissue and plasma ctDNA analysis (n5121) KRAS exon 3/4 point mutations.
Of the 50 plasma samples tested for those mutations, only 34 matched tumor-tissue samples were also analyzed for those mutations. Six mutant tumor-tissue samples (18%) and 13 mutant plasma samples (38%) were determined. Five mutant samples and 20 WT samples were concordant. One mutant tumor-tissue sample was determined WT by plasma analysis. Inversely, eight mutant plasma samples were determined WT by tumor-tissue analysis. Sensitivity, specificity, PPV and NPV were 83%, 71%, 38% and 95%, respectively (Table 2B; detailed data in supplementary Table S8 , available at Annals of Oncology online).
NRAS point mutations (n ¼ 34).
On the 50 plasma samples tested for NRAS mutations, only 34 tumor-tissue samples were also analyzed for NRAS testing. Three mutant tumor-tissue samples (9%) and 4 mutant plasma samples (12%) were determined. Two mutant samples and 29 WT samples were concordant. One mutant tumortissue sample was determined WT by ctDNA analysis. Conversely, two mutant plasma samples were determined as WT by tumortissue analysis. Sensitivity, specificity, PPV and NPV were 67%, 94%, 50% and 97%, respectively (Table 2B; detailed data in supplementary Table S8 , available at Annals of Oncology online). Apparent false negative results (n ¼ 13, supplementary data and Table S13 , available at Annals of Oncology online) might mostly be explained by (i) the large delay between collection of the surgical specimens and blood draw (n ¼ 7); (ii) by chemotreatment between biological source collection (n ¼ 4); (iii) by over-represented clones originating from under-represented clones at the time of tumor surgery or biopsy (n ¼ 4); and (iv) the limitation of the ctDNA analysis. Although the plasma assay contains rigorous quality controls theoretically impeding false positive data, we cannot rule out the presence of false positives. The concordance study as detailed by hotspot mutation is described in supplementary data, pp. 21-22, available at Annals of Oncology online (Supplemantary Table 3 ).
Quantitative multiparametric ctDNA analysis
As previously described [21] , IntPlex allows quantitative analysis of ctDNA. In this study, the median mutant ctDNA concentration was 19 ng/ml of plasma (0.012-135 ng/ml) and the median mutation load or the mutant allele frequency was 1.1% (n ¼ 99; 0.003%-100%) (supplementary Table S9 and pp. 22-25, available at Annals of Oncology online).
Post hoc discordance analysis
We extensively examined most of the factors that could result in discordance between tumor-tissue and plasma analysis for determining the mutational status of the tested genes. Examination of the factors potentially impacting sensitivity, specificity and concordance was made (described in supplementary data 'detailed discordance analysis' in pp. 27-35 and Tables  10 and 11 , available at Annals of Oncology online). Discordant samples' analysis revealed that tumor site (colon versus rectum or rectosigmoid junction), type of tissue analyzed (biopsy versus surgical specimen), tissue derived from primary tumor or metastasis, time-lapse between tissue and blood collection, resection of the primary tumor or the metastasis used for tumor-tissue analysis at time of blood sampling as well as the number and the localization of metastatic sites at time of blood sampling seem to affect concordance. Note, no statistically significant differences were found between groups. Individual examination of discordant samples is described in supplementary Tables S11-S13, available at Annals of Oncology online. (Figure 2 ). When studying the tumor molecular profile by ctDNA analysis, 91 samples out of the 119 harbored at least one mutation (76% of the 119 mCRC cohort) while 28 samples harbored no mutation (24%). Thirty-five samples had single RAS mutations (29%) and three samples were solely mutant for BRAF V600E (2%). Note that no plasma sample was exclusively mutant for NRAS. We found that 53 samples were multiple mutants (45%) (Figure 2) . The most prevalent combination of mutations was the concomitance of KRAS and NRAS point mutations since 24 samples harbored KRAS and NRAS point mutations (45% of the multiple mutant plasma cohort). Sixteen samples were multiple KRAS mutant (30%). Six samples were mutant for KRAS and BRAF (12%) and one sample was BRAF V600E and NRAS mutant (1%). Finally, we showed that six samples harbored co-occurring mutations in KRAS, NRAS and BRAF (11%) (Figure 2 ).
When using a sensitivity threshold of 0.5% mutant allele frequency, 36 samples were identified as single RAS mutant samples (30%), 9 samples as exclusively BRAF mutant (8%), 31 samples were determined multiple mutant (26%) and 43 samples were scored as WT (43%). Among those 31 multiple mutant samples, 20 harbored multiple KRAS mutations (65%), 8 samples harbored mutations on KRAS and NRAS (26%); 2 samples were KRAS and BRAF mutant (6%) and 1 sample was scored mutant for KRAS, NRAS and BRAF (3%) (Figure 2 ). When applying a sensitivity threshold of 0.1%, the proportions of single RAS mutant samples, single BRAF mutant samples, multiple mutant samples and WT samples were 29% (n ¼ 35), 4% (n ¼ 5), 40% (n ¼ 47) and 27% (n ¼ 32), respectively. Among the 47 multiple mutant samples, 17 were multiple KRAS mutant (36%), 21 were KRAS and NRAS mutant (45%), 7 were KRAS and BRAF mutant (15%) and 2 were mutant for KRAS, NRAS and BRAF (n ¼ 4%) (Figure 2 ).
Discussion
To confirm recent advances in the ctDNA field [8, 10, 13, 14, [23] [24] [25] and the first clinical validation of ctDNA in oncology [16] , we carried out this prospective, multicenter, blinded study on 140 mCRC patients to better evaluating of ctDNA clinical utility. Our assay is not intended to compare the analytical performance of one method for plasma testing with that of one method for tissue testing, but rather to examine the value of plasma analysis versus tissue analysis under standard management care.
Data turnaround time
Data turnaround-time for ctDNA analysis was shorter and less variable than for tumor-tissue analysis. Tumor-tissue analysis delay could be detrimental for the patients who would not be selected for a potentially better treatment with anti-EGFR because of the late availability of the test results. Note, liquid biopsy testing was carried out in a centralized lab dedicated to this specific analysis, whereas tissue testing was carried out at participating institutions and it so might be affected by several, local organizational problems. Therefore, the different turnaround time might not reflect true differences in the time required to complete the two analyses.
Evaluation of concordance
Mutation profiles obtained from tumor-tissue analysis correspond to that obtained from PRIME [26] and FIRE [27] studies. Those observations were consistent with PRIME description with the exception that the PRIME study did not report any multiple mutations Figure S4 , available at Annals of Oncology online). However, in contrast to our previous report, it appears, to be moderately concordant with that obtained when using plasma analysis. Thus, in contrast with our previous work applying the same IntPlex V R test and reporting very high accuracy with tumor-tissue analysis (96% for KRAS exon 2 mutations and 100% for BRAF V600E) [16] , ctDNA mutation testing was made here without any sensitivity cutoff while a threshold of >0.5% (mutant to WT ctDNA ratio) was used in our previous report. Consequently, ctDNA mutation testing here is much more sensitive (>50-fold) with a sensitivity ranging from 0.001% to 0.005% depending upon the mutations. One must consider also the issue of the sensitivity level of the methods used for tumor-tissue analysis. Sanger, pyrosequencing, NGS or Q-PCR-based techniques show various sensitivity (10%, 2%-5%, 1% and 0.1%, respectively) resulting in analytical variability [28] [29] [30] . It is assumed that there is a reasonable concordance between results by the different methods, but one can debate about their absolute preciseness as several factors could interfere with their reliability. We carried out an extensive examination of the various factors which may lead to discordance between tumor-tissue and plasma analysis. The data revealed that either the use of a biopsy or absence of a primarytumor in place at the time of blood draw or a long delay between tumor-tissue and blood collection mostly altered both specificity and sensitivity. As a consequence, a major limitation of tumortissue analysis is that sampling may not reflect tumor heterogeneity, especially in advanced cancers due to (i) intra-tumoral, (ii) inter-tumoral, and (iii) temporal heterogeneity [31] [32] [33] [34] [35] [36] [37] [38] . In light of much recent evidence, it is now clear that there is a consistent level of discordance ranging from 3.6% to 17.5% [32] of the RAS mutational status between primary and paired metastasis.
ctDNA analytical method and the sensitivity issue
Our data on the clinical utility of ctDNA analysis rely on the use of the robustness and reliability of our analytical method. IntPlex V R enables a single-copy detection of variant alleles down to an unprecedented sensitivity of !0.005% which is slightly higher to that of digital PCR and much higher than sequencing (0.1%-1%). Mutations with extremely low prevalence (0.005%) can be detected with very high sensitivity as experiments carried out under the Poisson law distribution unequivocally demonstrated that one mutated fragment can be reliably detected. Since there is no clear significance of low-prevalence RAS mutations in relation to the effectiveness of anti-EGFR therapy, one might also apply a sensitivity cutoff percentage filter [39] [40] [41] .
When applying a sensitivity cutoff of 0.5% as used in our previous study, 15 out of 26 plasma samples identified as 'false positive' for KRAS exon 2 would be scored WT, greatly improving the assay specificity (84% instead of 62%). Alternatively, 11 mutant plasma samples concordant with tumor-tissue would be scored as negative (significantly decreasing the sensitivity, 64% instead of 85%). As a consequence, the need for a threshold of sensitivity as previously observed for tumor-tissue cannot be applied to plasma analysis. Sensitivity as termed for tumor-tissue analysis neither corresponds nor directly correlates with that determined from ctDNA. Sensitivity directly correlates with the number of malignant cells harboring the mutation from a macro-or micro-dissected region of a tissue section. This is not the case for ctDNA due to the significant circulating DNA release from the micro-environment cells occasionally resulting in high circulating DNA amounts as illustrated by the wide variation of the ctDNA mutation allelic frequency (0.003%-99%) [15, 21] .
However, patients with a very low number of mutant cells within the tumor mass should theoretically benefit from first line anti-EGFR therapy and consequently, a sensitivity threshold when analyzing ctDNA might be used. While our assay in this study, without any threshold, scored 24% as WT mCRC patients, 27% and 36% would be scored WT when using a 0.1% and 0.5% detection cutoff, respectively. However, 9% and 2.5%, respectively, would appear as false negatives when compared with tumor-tissue, so illustrating the difficulty in applying a sensitivity threshold for ctDNA analysis. Stringent studies on the clinical response to anti-EGFR monotherapy regimen and use of a quantitative ctDNA detection method (such as IntPlex) might help in determining a reproducible threshold for treatment guidance [41] .
Impact of our study on the demonstration of clinical utility of plasma DNA analysis
We explored the clinical outcome of patients being established WT by tumor-tissue analysis while mutant by plasma analysis and, consequently treated with anti-EGFR to address this issue. However, in addition to the low number of this set of patients, this examination is biased by the concomitant use of chemotherapy with anti-EGFR therapy. Altogether, the clinical data on those discordant patients do not appear contradictory to the mutational status as determined by plasma analysis. The moderate concordance found in this study (72%, 74% and 87% of accuracy for KRAS exon 2, KRAS exon 3, 4 and BRAF V600E, respectively) is due to higher mutation frequency found by plasma analysis. In comparison with tumor-tissue analysis, a blood test appears more costeffective for genotyping-guided clinical care. In addition, rapid data turn-around time helps the oncologist to rapidly enroll mCRC patients that can benefit from anti-EGFR therapy. Long delays sometimes occurring only with tumor-tissue analysis preclude a significant group of patients to be treated by such an appropriate therapy. The limited number of anti-EGFR-treated patients precluded enough statistical power to initiate assessment of clinical utility in terms of concordance of ctDNA status from plasma with patient follow-up. However, there is here a clear demonstration that ctDNA provides strong evidence for a more rapid data turnaround time than tumor-tissue analysis, irrespective of the methods used. It is vital that the turnaround time is as short as possible to ensure that a treatment decision can be made quickly. Ideally this should be no more than seven working days, to ensure that all possible treatment options are available to a patient as soon as possible. ESMO consensus guidelines for the management of patients with mCRC [1] indicate that a fast initiation of targeted therapy as a first-line treatment is crucial for cancer patients as it increases overall survival rates. Thus, a timely detection of biomarkers is extremely important, reducing both patient anxiety while waiting for results and ensuring the best possible treatment. ESMO recommendation 4 stated that 'RAS testing should be carried out on all patients at the time of diagnosis of mCRC' and that RAS testing Turnaround time for RAS testing (expanded RAS analysis) should be 7 working days from the time of receipt of the specimen by the testing laboratory to the time of issuing of the final report, for->90% of specimens [1] . Thus, this study constitutes an initial report demonstrating clinical utility with regards to the data turnaround time of using ctDNA analysis for testing RAS and BRAF mutational status in mCRC patients.
Conclusion
To date, there is no other report showing such an increase of mutation detection in comparison with tumor-tissue analysis and such a high proportion of co-occurring mutations. Therefore, mutation profiling based on ctDNA analysis may identify concomitant resistance mechanisms residing in separate metastases and within a tumor mass potentially enabling longitudinal assessment of the effect of therapies designed to overcome resistance. The liquid biopsy, by analyzing ctDNA especially, has important advantages over tissue biopsy in terms of more accurately detecting key mutations due to various issues mainly clonal intra-and inter-tumor heterogeneity [42] , and dynamic genetic changes in the course of tumor growth and treatment over time [42] [43] [44] .
In contrast, ctDNA analysis represents a wider genetic picture of the entire tumor mass and evaluates primary tumor and metastases with one sample so providing snapshot information of tumor dynamics in real-time. In the light of these issues, obtaining a higher mutation level as determined here with an ultrasensitive plasma test is common-sense. Ultrasensitive ctDNA analysis might otherwise result in further population selection of superresponders to anti-EGFR therapy. Lastly, we report here the first complete mutation profile with all actionable RAS and BRAF mutations in a large cohort of patients at time of mCRC diagnosis to guide anti-EGFR treatment decisions. By presenting the variation of this mutation profile with using various detection thresholds, our data illustrate the power of ctDNA analysis pointing out the importance of the test sensitivity in particular in adjusting the clinically relevant use of targeted agents. ctDNA provides a representation of the malignant disease as a whole and could be a reliable source of diagnostic DNA to replace the tumor-tissue. Plasma testing may be initially used when either a biopsy is insufficient for genotyping or cannot be obtained safely or when tumor-tissue is not available. Thus, this study represents one step closer to clinical routine implementation of ctDNA analysis to guide anti-EGFR treatment decision in mCRC.
